Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-cetuximab PET optimization study in metastatic colorectal cancer
NL-OMON25781Active, not recruiting
- Sponsor
- VU Univeristy Medical Center
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by VU Univeristy Medical Center. Primary endpoints: Tumor uptake of 89Zr-cetuximab in non-hepatic lesions and Association between 89Zr-cetuximab uptake and RECIST response. Started Dec 2011; status: active, not recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON25781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25781.